WilmerHale represented the underwriters in Kymera Therapeutics’ public offering of 5,899,500 shares of common stock and pre-funded warrants to purchase 655,500 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 855,000 additional shares of common stock. Kymera, a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), received approximately $288 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. 

The WilmerHale team representing the underwriters included Lisa Firenze, Andrew Langworthy, Matt Kosior, Kevin Cheng, Justin Flaumenhaft and Whitley Horning with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.